公司

Ultragenyx Pharmaceutical

关注打开结构图就此提问研究这家公司

简介

总部: US

结论

结合来源阅读结论，展开条目查看证据。

事实证据 1

share price changerose more than 3%

暂无可公开的证据摘要。

GDELT Global Knowledge Graph · 2026-10-08 05:15

查看证据

媒体GDELT Global Knowledge Graph2026-10-08 05:15
查看来源

事实证据 1

prv sale agreement value$210 million

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.

GlobeNewswire public company news · 2026-10-07 20:30

查看证据

公司披露GlobeNewswire public company news2026-10-07 20:30
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
查看来源

显示第 1 至 2 条，共 2 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

暂无: 公司信号 · 关系 · 财务数据 · 披露文件 · 业绩指引